Previous close | 6.1158 |
Open | 0.0000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | N/A |
Market cap | 29.583M |
Beta (5Y monthly) | 1.33 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.3450 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
LYON, France, January 30, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the publication of the January 2023 Letter to Shareholders.
LYON, France, January 23, 2023--Regulatory News: Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on December 31st, 2022:
LYON, France, January 16, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, releases its total number of outstanding shares as well as its voting rights as of December 31st, 2022.